Financial Data and Key Metrics Changes - The company reported a mid-single-digit organic revenue growth of 5.2% for Q3 2024, driven by strong volume and share gains across the portfolio [5][21] - Adjusted gross margin increased to 54.3%, and adjusted operating margin rose to 25.2%, reflecting a year-over-year increase of 170 basis points and 220 basis points respectively [24] - Adjusted diluted EPS grew by 18.2% year-over-year, reaching $3.50 [24] Business Line Data and Key Metrics Changes - BD Medical segment growth was led by strong performance in infusion systems, particularly the BD Alaris, which returned to market [21] - Pharmaceutical Systems experienced double-digit growth in prefilled devices for biologic drugs, primarily GLP-1s, despite some transitory market dynamics [22][13] - BD Life Sciences saw high single-digit growth in specimen management, although it faced lower market demand for instruments due to transitory dynamics [22] - BD Interventional reported high single-digit growth in UCC, with continued double-digit growth in the PureWick franchise [23] Market Data and Key Metrics Changes - Over 90% of the company's revenue grew by more than 6% organically across its three largest geographies, although there was a decrease in China due to ongoing market dynamics [21] - The company noted strong volume growth in MDS in China, despite price pressure from VBP dynamics [65] Company Strategy and Development Direction - The company is advancing its BD 2025 strategy, focusing on growth through innovation and tuck-in M&A, simplification through BD Excellence, and empowering the organization [6][19] - The acquisition of Critical Care is expected to enhance the connected care strategy and contribute to margin and earnings growth [7] - The company aims to expand its healthcare automation and informatics AI business to over $5 billion, with a long-term view of exceeding $7 billion by 2030 [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to outperform market dynamics and achieve strong financial performance in FY '25, despite ongoing challenges in certain markets [28][29] - The company anticipates continued strong performance in the connected medication management portfolio, particularly with Alaris, and expects to exceed its adjusted operating margin goal of 25% [28][37] Other Important Information - The company has achieved over 100% year-to-date growth in free cash flow, with a conversion rate above 80% [6][25] - The company is on track to reduce its manufacturing network by over 20% and is investing in smart factories to enhance productivity [18][19] Q&A Session Summary Question: Guidance for Q4 and revenue expectations - Management indicated that Q4 revenue guidance implies upper 6% organic growth, driven by continued momentum from Alaris and favorable comparisons from the previous year [30][33] Question: Revenue growth drivers beyond Alaris - Management highlighted strong growth in consumables and upcoming product launches, including the next-generation Pyxis platform, as key growth drivers beyond Alaris [52][53] Question: Dynamics in China and market recovery - Management noted that while there are transitory dynamics affecting performance in China, they expect long-term recovery in research investment and continued strong volume growth in MDS [64][65]

Becton Dickinson (BDX) reported $4.99 billion in revenue for the quarter ended June 2024, representing a yearover-year increase of 2.3%. EPS of $3.50 for the same period compares to $2.96 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $5.07 billion, representing a surprise of -1.57%. The company delivered an EPS surprise of +5.74%, with the consensus EPS estimate being $3.31. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ...

Becton Dickinson (BDX) came out with quarterly earnings of $3.50 per share, beating the Zacks Consensus Estimate of $3.31 per share. This compares to earnings of $2.96 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 5.74%. A quarter ago, it was expected that this medical device manufacturer would post earnings of $2.96 per share when it actually produced earnings of $3.17, delivering a surprise of 7.09%. Over the last four qu ...

Exhibit 99.1 Contacts: Investors: Adam Reiffe, Sr. Director, Investor Relations - 201-847-6927 Media: Troy Kirkpatrick, VP, Public Relations - 858-617-2361 BD Reports Third Quarter Fiscal 2024 Financial Results Strong Margin Execution Drives Performance in Quarter • Revenue of $5.0 billion as reported, adjusted revenue of $5.1 billion, driven by strong organic revenue growth • GAAP and adjusted diluted EPS of $1.68 and $3.50 grew 23.5% and 18.2%, respectively • Year-to-date Cash from Continuing Operations g ...

Strong Margin Execution Drives Performance in Quarter Revenue of $5.0 billion as reported, adjusted revenue of $5.1 billion, driven by strong organic revenue growth GAAP and adjusted diluted EPS of $1.68 and $3.50 grew 23.5% and 18.2%, respectively Year-to-date Cash from Continuing Operations grew 60% to $2.7 billion and Free Cash Flow grew over 100% to $2.2 billion, increasing $1.0 billion and $1.2 billion since the prior year, respectively The company updated its fiscal 2024 GAAP revenue growth guidance t ...

Let's check out the factors that have shaped BDX's performance prior to this announcement. In April, BD's Biosciences business unit announced the global commercial release of the three- and four-laser additions to the BD FACSDiscover S8 Cell Sorter family, which complement the five-laser instrument launched last year. In February, BD announced a strategic partnership with Camtech Health to increase access to cervical cancer screening in Singapore through the country's first-ever program to offer at-home sel ...

Core Insights - BD and Quest Diagnostics have entered a global collaboration to develop, manufacture, and commercialize flow cytometry-based companion diagnostics aimed at improving treatment selection for cancer and other diseases [1][2]. Company Overview - BD is a leading global medical technology company with over 70,000 employees, focused on advancing health through innovative technology and solutions [5]. - Quest Diagnostics is a major player in diagnostic information services, serving one in three adult Americans and half of the physicians and hospitals in the U.S. with nearly 50,000 employees [6]. Collaboration Details - The collaboration will provide the pharmaceutical industry with an end-to-end solution for companion diagnostics, covering everything from exploratory panel development to the manufacturing and distribution of FDA-approved diagnostic kits [2][4]. - The partnership combines BD's expertise in flow cytometry with Quest's capabilities in biomarker and assay development, aiming to bring novel companion diagnostics to market [3][4]. Technology and Impact - Flow cytometry is highlighted as a critical technology that can rapidly analyze and sort individual cells, providing insights into patients' immune responses and aiding in the selection of first-line therapies for cancer patients [3]. - The use of companion diagnostics is expected to enhance patient outcomes and reduce healthcare costs by enabling more precise healthcare [4].

FRANKLIN LAKES, N.J., July 23, 2024 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $0.95 per common share, payable on September 30, 2024 to holders of record on September 9, 2024. The indicated annual dividend rate is $3.80 per share. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving ...

Becton Dickinson (BDX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. The power of a ...

Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Becton Dickinson (BDX) or Merit Medical (MMSI) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate ...